Connect with an MSL
Find a Medical Science Liaison (MSL) in your region and specialty.
Phase 1/2 HORIZEN clinical trial
Enzomenib in Relapsed/Refractory and Newly-Diagnosed Acute Leukemia
An ongoing Phase 1/2 study (NCT04988555) investigating enzomenib in patients with acute leukemia and other selected hematologic malignancies, including those with KMT2A-rearranged or NPM1-mutated subtypes, high-risk MDS, and relapsed/refractory MM
Menin is a key mediator of oncogenic signaling in acute leukemias characterized by KMT2A (mixed-lineage leukemia [MLL]) rearrangements and NPM1 mutations. Enzomenib (DSP‑5336) is an investigational, orally administered menin inhibitor.
Other Names
DSP-5336
Modality
Small molecule menin inhibitor (oral)
KMT2A, histone-lysine N‑methyltransferase 2A; MM, multiple myeloma; MDS, myelodysplastic syndrome; MLL, mixed-lineage leukemia; NPM1, nucleophosmin 1.
Enzomenib (DSP-5336) is currently being evaluated in adults and eligible adolescents (≥12 years who weigh ≥40 kg for monotherapy, country/site specific) with acute leukemia harboring KMT2A (MLL) rearrangements or NPM1 mutations.
The ongoing Phase 1/2 trial, A Study of DSP-5336 in Acute Leukemia and Other Selected Hematologic Malignancies, With and Without MLL Rearrangement or NPM1 Mutation is a multicenter, open-label, dose-escalation and expansion study assessing the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of enzomenib as monotherapy and in combination regimens.
Primary Objectives:
Primary Objective:
Secondary Objectives:
AE, adverse events; AML, acute myeloid leukemia; AUClast, area under the curve to the last measurable concentration; Cmax, maximum observed drug concentration; CR, complete response; CRc, complete response composite; CRh, or complete remission with partial hematologic recovery; CRi, or complete remission with incomplete hematologic recovery; KMT2A, histone-lysine N‑methyltransferase 2A; MLL, mixed-lineage leukemia; NPM1, nucleophosmin 1; PK, pharmacokinetics; SAE, serious adverse events; t1/2, elimination half-life.
R/R acute leukemia with KMT2Ar or R/R AML with NPM1m
High-risk R/R MDS after HMA or refractory MM (select sites/regions)
R/R acute AML with KMT2Ar or NPM1m
R/R acute AML with FLT3m + NPM1m or KMT2Ar
AML with KMT2Ar (fit or unfit) or with NPM1m (unfit)
AML with KMT2Ar or NPM1m
AML, acute myeloid leukemia; FLT3m, fms-like tyrosine kinase 3 mutation; HMA, hypomethylating agent; KMT2Ar, histone-lysine N‑methyltransferase 2A rearrangement; MDS, myelodysplastic syndrome; MM, multiple myeloma; NPM1m, nucleophosmin 1 mutation; R/R, relapsed or refractory.
Phase 1 R/R:
Phase 1 Newly Diagnosed:
Phase 2 R/R:
AML, acute myeloid leukemia; CAR-T, chimeric antigen receptor–T cell; CNS, central nervous system; CYP3A4/5, cytochrome P450 family 3 subfamily A member 4/5; ECOG, Eastern Cooperative Oncology Group; HIV, human immunodeficiency virus; HSCT, hematopoietic stem cell transplant; KMT2Ar, histone-lysine N‑methyltransferase 2A rearrangement; LVEF, left ventricular ejection fraction; NPM1m, nucleophosmin 1 mutation; QTcF, QT interval corrected for heart rate using Fridericia's formula; R/R, relapsed or refractory; WBC, white blood cell; WHO, World Health Organization.
Phase 1:
Phase 2:
Exploratory analyses include minimal residual disease (MRD) negativity and molecular correlates of response and resistance.
AE, adverse events; AUClast, area under the curve to the last measurable concentration; Cmax, maximum observed drug concentration; CR, complete response; CRc, complete response composite; CRh, or complete remission with partial hematologic recovery; CRi, or complete remission with incomplete hematologic recovery; PK, pharmacokinetics; RP2D, recommended phase 2 dose; SAE, serious adverse events; t1/2, elimination half-life.
This global study is currently enrolling across the United States, Belgium, Canada, France, Italy, Japan, Singapore, South Korea, Spain, Switzerland, Taiwan, and the United Kingdom. Enter your ZIP code or explore the map to find active sites closest to your location.
This study site locator serves as a tool to connect healthcare professionals with the most accessible study site in the area for their patients.
Providers should contact the center directly or the Sumitomo Pharma America, Inc. study contact for enrollment and more information.
Study Contact: Matt Hitron, MD
Download the study information document and access the full study record, including eligibility criteria and site locations, at ClinicalTrials.gov (NCT04988555).
Find a Medical Science Liaison (MSL) in your region and specialty.
Sign up to receive the latest clinical data, scientific resources and news from Sumitomo Pharma America Medical Affairs.
Our Medical Information team can help you find the information you need.
+1 (800) 739-0565Monday–Friday, 8 AM–8 PM ET
24 hours, 7 days a week
Please report any side effects related to any Sumitomo Pharma America, Inc. medication by contacting us. You may also contact the US Food and Drug Administration (FDA) directly by visiting www.fda.gov/Safety/MedWatch or calling 1-800-FDA-1088.